Diarrhea News and Research

Latest Diarrhea News and Research

Takeda receives FDA approval for VELCADE sNDA to treat MM

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE (bortezomib) for Injection, which updates the label to include additional long-term overall survival (OS) data from the VISTA trial.

2 Nov 2011

New Mayo Clinic social network connects global community of esophageal cancer patients

In 2008, physicians at Mayo Clinic Florida led by Herbert Wolfsen, M.D., were looking for new ways to keep in touch with the large group of esophageal cancer patients cared for by him and other gastroenterologists and surgeons. Telephone calls, faxes and email had worked to create a network of patients but many now wanted interactive and remote access capability to share their experiences and challenges with this serious disease.

1 Nov 2011

Study evaluates availability of information about cosmetic ingredients for celiac patients

The lack of readily available information about cosmetic ingredients may cause patients with celiac disease who use lip, facial or body products to unknowingly expose themselves to gluten—an ingredient they need to avoid, according to the results of a new study unveiled today at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC.

1 Nov 2011

Emotional and psychological traumas may contribute to adult IBS

The psychological and emotional traumas experienced over a lifetime--such as the death of a loved one, divorce, natural disaster, house fire or car accident, physical or mental abuse—may contribute to adult irritable bowel syndrome (IBS), according to the results of a study unveiled today at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC.

1 Nov 2011

Mayo Clinic develops Microscopic Colitis Disease Activity Index

Mayo Clinic researchers have developed a new way to assess a common cause of chronic diarrhea, microscopic colitis, using the Microscopic Colitis Disease Activity Index.

1 Nov 2011

NPS announces new data from GATTEX Phase 3 study on short bowel syndrome

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced new data from STEPS 2, a long-term open-label study, showing that GATTEX (teduglutide) was associated with achieving and maintaining clinically meaningful reductions in parenteral nutrition (PN) and intravenous (IV) fluid volume in adult subjects with short bowel syndrome.

1 Nov 2011

Colonoscopic FMT effective in treating IBD, C.difficile-associated diarrhea

Growing evidence for the effectiveness of fecal microbiota transplants as a treatment for patients with recurrent bouts of Clostridium difficile (C.difficile) associated diarrhea is presented in three studies -- including a long-term follow-up of colonoscopic fecal microbiota transplant (FMT) for recurrent C. difficile Infection that included 77 patients from five different states-- unveiled today at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC.

1 Nov 2011

UCB to present new data on Cimzia at ACG annual scientific meeting

UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, will present new data on Cimzia at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place in Washington D.C. from October 28 to November 2.

1 Nov 2011

Limited alcohol consumption can cause gastrointestinal problems

Just one drink per day for women -- two for men -- could lead to small intestinal bacterial overgrowth (SIBO) and subsequently cause gastrointestinal symptoms like bloating, gas, abdominal pain, constipation and diarrhea, according to the results of a new study unveiled today at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC.

31 Oct 2011

Nursing home residence may allow for 'on-admission' prediction model of C. difficile infection severity

Antibiotics may not be the only risk factor associated with community-acquired Clostridium difficile infection, indicating that other undefined causes of the potentially life-threatening infection may exist and could also predict whether or not a patient will require hospitalization, according to the results of the study, "Predictors of Hospitalization in Community-Acquired Clostridium difficile Infection."

31 Oct 2011

'Good bugs' promising against ulcerative colitis, psoriasis, chronic fatigue syndrome

In four different studies presented at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC, researchers explored the effectiveness of probiotics for antibiotic-associated diarrhea; as an anti-inflammatory agent for patients with ulcerative colitis, psoriasis and chronic fatigue syndrome; and for people with abdominal discomfort and bloating who have not been diagnosed with a functional bowel disorder, such as irritable bowel syndrome (IBS).

31 Oct 2011

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for NUCYNTA ER (tapentadol) extended-release tablets, an oral analgesic, for the management of neuropathic pain associated with diabetic peripheral neuropathy in adults.

31 Oct 2011

Avanir seeks EMA marketing authorization for NUEDEXTA to treat pseudobulbar affect

Avanir Pharmaceuticals, Inc. announced today that it has submitted an application to the European Medicines Agency seeking marketing authorization for NUEDEXTA (dextromethorphan HBr and quinidine sulfate) for the treatment of pseudobulbar affect.

31 Oct 2011

EC approves Lilly's ALIMTA as continuation maintenance therapy for NSCLC

Eli Lilly and Company announced today that the European Commission has granted approval for the use of ALIMTA (pemetrexed for injection) as a single agent for continuation maintenance therapy in patients with a particular type of lung cancer, called advanced nonsquamous non-small cell lung cancer

29 Oct 2011

American College of Gastroenterology to hold special briefing for journalists

The American College of Gastroenterology will hold a special briefing for journalists at its 76th Annual Scientific meeting in Washington, DC highlighting new clinical science that explores the role of the "gut microbiota" - the bacterial composition of the GI tract - and the efficacy of probiotics in treating various GI conditions, including antibiotic-associated diarrhea, abdominal discomfort and bloating.

28 Oct 2011

Over-the-counter 'thyroid support' supplements could be dangerous

People who use over-the-counter "thyroid support" supplements may be putting their health at risk, according to a study being presented at the annual meeting of the American Thyroid Association. The supplements contain varying amounts of two different kinds of thyroid hormones apparently derived in large part from chopped up animal thyroid glands, says the study's senior investigator, Victor Bernet, M.D., an endocrinologist at Mayo Clinic in Florida.

28 Oct 2011

EC approves Pfizer's pneumococcal conjugate vaccine, Prevenar 13

Pfizer Inc. announced today that the European Commission has approved the Company's pneumococcal conjugate vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine, for active immunization for the prevention of vaccine-type invasive disease caused by Streptococcus pneumoniae in adults aged 50 years and older.

27 Oct 2011

Gilead, Bristol-Myers Squibb to develop and commercialize fixed-dose combination for HIV

Bristol-Myers Squibb Company and Gilead Sciences, Inc. today announced a licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing Bristol-Myers Squibb's protease inhibitor REYATAZ (atazanavir sulfate) and Gilead's cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing.

27 Oct 2011

Vertex initiates INCIVEK combination Phase 3b study for hepatitis C

Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called CONCISE that will evaluate the potential for treatment with INCIVEK (telaprevir) combination therapy to be shortened to 12 weeks in people with genotype 1 chronic hepatitis C who have the 'CC' variation near the IL28B gene.

24 Oct 2011

FDA's ODAC to review Affymax peginesatide NDA for treatment of CKD-associated anemia

Affymax, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will review the New Drug Application (NDA) for peginesatide proposed for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis on December 7, 2011 during the afternoon session.

24 Oct 2011